Looks as though they recruited 5 out of the 6 patients they had sought for the meningioma treatment trial and completed in September 19. The trial got a mention in the IPO propectus
I also haven't yet been able to find out any subsequent trial information to date but meningioma is no longer mentioned as a target tumour market in a recent Clarity Pharmaceutical presentation. Maybe all they wanted was safety data from this to pursue the Neuroblastoma trial in the US.
Our closest competitor in the existing PRRT market is Luthera (Lu177 dotatate) . They have a 6 year trial going in the US for surgically unresectable meningioma which reports in 2025. If it works for Luthera it will likely work for Cu67. They may as well do the work for us so we don't have to spread to thin.
ASX: CU6 Outlook., page-23
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.27 |
Change
0.110(1.54%) |
Mkt cap ! $2.326B | |||
| Open | High | Low | Value | Volume |
| $7.10 | $7.28 | $7.07 | $7.095M | 986.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 411 | $7.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.30 | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |